Irinotecan is under clinical development by Ascelia Pharma and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Irinotecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Irinotecan (SOL-901) is under development for the treatment of metastatic colorectal cancer (CRC), cholangiocarcinoma, colon cancer, pancreatic cancer, prostate cancer, gastric cancer and adenocarcinoma of the gastroesophageal junction. It is administered through oral route in the form of tablet. It acts by targeting DNA topoisomerase I. The drug candidate is developed based on formulation technology.
Ascelia Pharma overview
Ascelia Pharma, is an oncology drug development company. Its product pipeline includes Mangoral (manganese chloride tetrahydrate), a liver imaging drug for diagnostic use as a magnetic resonance imaging (MRI) contrast agent under development for the enhancement of the liver tissue; detection and localization of liver metastases; and severe renal insufficiency. The company also has another pipeline product, Oncoral, is an oral formulation of the topoisomerase inhibitor irinotecan with an anti-tumor effect and a chemotherapeutic agent for the treatment of advanced gastric (stomach) cancer. The company has operations in Sweden and the US. Ascelia Pharma is headquartered in Malmo, Sweden.
For a complete picture of Irinotecan’s drug-specific PTSR and LoA scores, buy the report here.